BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26099018)

  • 1. The TET2 interactors and their links to hematological malignancies.
    Pan F; Weeks O; Yang FC; Xu M
    IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis.
    Cheng J; Guo S; Chen S; Mastriano SJ; Liu C; D'Alessio AC; Hysolli E; Guo Y; Yao H; Megyola CM; Li D; Liu J; Pan W; Roden CA; Zhou XL; Heydari K; Chen J; Park IH; Ding Y; Zhang Y; Lu J
    Cell Rep; 2013 Oct; 5(2):471-81. PubMed ID: 24120864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
    Nakajima H; Kunimoto H
    Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies.
    Li W; Xu L
    Oncol Res Treat; 2019; 42(6):309-318. PubMed ID: 31055566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET2 in Normal and Malignant Hematopoiesis.
    Bowman RL; Levine RL
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28242787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connections between TET proteins and aberrant DNA modification in cancer.
    Huang Y; Rao A
    Trends Genet; 2014 Oct; 30(10):464-74. PubMed ID: 25132561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.
    Mahfoudhi E; Talhaoui I; Cabagnols X; Della Valle V; Secardin L; Rameau P; Bernard OA; Ishchenko AA; Abbes S; Vainchenker W; Saparbaev M; Plo I
    DNA Repair (Amst); 2016 Jul; 43():78-88. PubMed ID: 27289557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.
    Madzo J; Vasanthakumar A; Godley LA
    Semin Hematol; 2013 Jan; 50(1):61-9. PubMed ID: 23507484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
    Li R; Xu MJ; Yang FC; Zhou Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tet2-mediated DNA demethylation regulates the proliferation and apoptosis of human leukemia K562 cells.
    Qiao Y; Zhou Y; Yang H; He Z; Fan A
    Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):23-27. PubMed ID: 37300692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.
    Wang P; Yan Y; Yu W; Zhang H
    Cell Prolif; 2019 Jul; 52(4):e12626. PubMed ID: 31033072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insight into substrate preference for TET-mediated oxidation.
    Hu L; Lu J; Cheng J; Rao Q; Li Z; Hou H; Lou Z; Zhang L; Li W; Gong W; Liu M; Sun C; Yin X; Li J; Tan X; Wang P; Wang Y; Fang D; Cui Q; Yang P; He C; Jiang H; Luo C; Xu Y
    Nature; 2015 Nov; 527(7576):118-22. PubMed ID: 26524525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
    Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
    Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.
    Yang H; Liu Y; Bai F; Zhang JY; Ma SH; Liu J; Xu ZD; Zhu HG; Ling ZQ; Ye D; Guan KL; Xiong Y
    Oncogene; 2013 Jan; 32(5):663-9. PubMed ID: 22391558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-Eleven-Translocation Genes in Cancer.
    Wang Y; Wang X; Lu J
    Cancer Treat Res; 2023; 190():363-373. PubMed ID: 38113007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
    Poole CJ; Lodh A; Choi JH; van Riggelen J
    Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine.
    Minor EA; Court BL; Young JI; Wang G
    J Biol Chem; 2013 May; 288(19):13669-74. PubMed ID: 23548903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.